VALIRX ORD 0.1P overview

Hardman & Co Research Hardman & Co Research: Valirx (VAL): VAL401 is going forward 15-Apr-2019 / 07:15 GMT/BST Hardman & Co Research: VAL401 is going forward VAL is a clinical-stage biopharmaceutical company focused on the development of therapeutics for the treatment of cancer. The company has two leading assets: VAL201 (Phase I/II) - a peptide for advanced prostate cancer and potential to treat other hormone-induced indications; and VAL401 (completed Phase II) - a novel reformulation of...

Hardman & Co Research Hardman & Co Research: ValiRx (VAL): VAL401 Phase II trial completed 01-Nov-2018 / 07:15 GMT/BST Hardman & Co: VAL401 Phase II trial completed ValiRx (VAL) is a clinical-stage biopharmaceutical company focused on the development of therapeutics for the treatment of cancer. The company's two leading assets are in clinical trials: VAL201 (Phase I/II) - a peptide for advanced prostate cancer and potential to treat other hormone- induced indications; and VAL401 (Phase II) - a...

Hardman & Co Research Hardman & Co Research: ValiRx (VAL): 2017: a pivotal year 20-Apr-2018 / 10:43 GMT/BST Hardman & Co Research: 2017: a pivotal year ValiRx (VAL) is a clinical-stage biopharmaceutical company focused on the development of therapeutics for the treatment of cancer. The company's two leading assets are in clinical trials: VAL201 (Phase I/II) - a peptide for advanced prostate cancer and potential to treat other hormone- induced indications; and VAL401 (Phase II) - a novel...

VIDEO FINANCIAL REPORTING Why invest in is the first financial video platform where you can easily search through thousands of videos describing global ......